Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share and update on their drug NP-251 or Repirinast which is being investigated in treatment of chronic kidney disease. Moreau telling Proactive the pre-clinical animal model of kidney fibrosis, seems to show Repirinast reduced fibrosis by 50% with statistical significance. As part of the new CKD research program, the Company will also investigate the use of Repirinast in acute interstitial nephritis, which causes inflammation of parts of the kidney.
Algernon Pharmaceuticals provides update on chronic kidney disease research program with NP-251
